Jump to main content
Jump to site search

Issue 19, 2020
Previous Article Next Article

The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine

Author affiliations

Abstract

The immunosuppressive tumor microenvironment enables cancer to resist immunotherapies. We have established that intratumoral administration of plant-derived Cowpea mosaic virus (CPMV) nanoparticles as an in situ vaccine overcomes the local immunosuppression and stimulates a potent anti-tumor response in several mouse cancer models and canine patients. CPMV does not infect mammalian cells but acts as a danger signal that leads to the recruitment and activation of innate and subsequently, adaptive immune cells. In the present study we addressed whether other icosahedral viruses or virus-like particles (VLPs) of plant, bacteriophage and mammalian origin can be similarly employed as intratumoral immunotherapy. Our results indicate that CPMV in situ vaccine outperforms Cowpea chlorotic mottle virus (CCMV), Physalis mosaic virus (PhMV), Sesbania mosaic virus (SeMV), bacteriophage Qβ VLPs, or Hepatitis B virus capsids (HBVc). Furthermore, ex vivo and in vitro assays reveal unique features of CPMV that makes it an inherently stronger immune stimulant.

Graphical abstract: The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine

Back to tab navigation

Supplementary files

Article information


Submitted
22 Jul 2020
Accepted
01 Sep 2020
First published
11 Sep 2020

Biomater. Sci., 2020,8, 5489-5503
Article type
Paper

The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine

S. Shukla, C. Wang, V. Beiss, H. Cai, T. Washington, A. A. Murray, X. Gong, Z. Zhao, H. Masarapu, A. Zlotnick, S. Fiering and N. F. Steinmetz, Biomater. Sci., 2020, 8, 5489
DOI: 10.1039/D0BM01219J

Social activity

Search articles by author

Spotlight

Advertisements